SynAct Pharma AB
Research SynAct Pharma AB (SYNACT) on Bullrun: market cap SEK 843.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSYNACT
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 843.33M
- Financial periodFY2024
- Net income-SEK 82.40M
Valuation Snapshot
latest market cap is SEK 843.33M.
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy.
Frequently asked questions
What is SynAct Pharma AB's market cap?
SynAct Pharma AB's market capitalization is SEK 843.33M.
What does SynAct Pharma AB do?
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis;